Inogen, Inc.
NASDAQ:INGNMedical - Devices
+$0.05 today
- Market cap
- $144.83M
- Beta
- 1.59
- P/E (TTM)
- -7.0
- EPS (TTM)
- -$0.91
Volume 0.19M
Average 0.33M
INGN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Inogen, Inc.NASDAQ: INGN
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $5.1M rose 26.4% year over year, ahead of the +7.3% change in trailing-twelve-month research & development. Sequentially, it fell 4.1% from the prior quarter. Over 3 fiscal years it compounded at -4.0% a year.
Context
- Research & development amounted to 5.6% of revenue in FY2025, down 0.9 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +26.4% holds above the trailing-twelve-month pace of +7.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 19.4M USD
- Year-over-year change
- -10.2%
- 4-year CAGR
- +4.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 19.4M | -10.2% |
| FY2024 | 2024-12-31 | 21.61M | +3.7% |
| FY2023 | 2023-12-31 | 20.84M | -5.0% |
| FY2022 | 2022-12-31 | 21.94M | +32.4% |
| FY2021 | 2021-12-31 | 16.58M | — |
Research & Development vs competitors
How INGN compares with its peers on the latest reported figures
- INGN's LTM Mar 2026 research & development of $20.46M is the 6th highest of the 11 companies compared; the peer median is $20.29M.
- Its year-over-year change of +7.3% is the 5th highest of 11, against a peer median of -4.0%.
- Research & development amounts to 5.8% of revenue for INGN, versus a peer median of 18.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $85.68M | +76.6% | +218.7% | 13864.6% | |
| LTM Mar 2026 | $44.26M | -24.0% | -13.0% | 14.6% | |
| LTM Mar 2026 | $33.21M | -3.4% | +10.2% | 22.9% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $27.18M | +72.6% | +29.4% | — |
| LTM Mar 2026 | $21.34M | -31.8% | -24.3% | 18.1% | |
| LTM Mar 2026 | $20.46M | +7.3% | -4.0% | 5.8% | |
| LTM Dec 2025 | $19.24M | -4.7% | -10.1% | 147.7% | |
| LTM Mar 2026 | $12.72M | -28.5% | -13.9% | 16.0% | |
| LTM Mar 2026 | $9.9M | +98.0% | — | 18.4% | |
| LTM Mar 2026 | $2.57M | -32.8% | -6.3% | 26.8% | |
| LTM Mar 2026 | $1.81M | +151.4% | +33.6% | 4.1% | |
| Peer median (excluding INGN) | $20.29M | -4.0% | -6.3% | 18.4% | |
Competitors are the stored peer set for INGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 358M | 377.24M | 315.66M | 335.71M | 348.67M |
| Cost of Revenue | 181.52M | 223.71M | 188.96M | 180.96M | 182.78M |
| Gross Profit | 176.48M | 153.53M | 126.7M | 154.74M | 165.89M |
| Gross Margin | 49.3% | 40.7% | 40.1% | 46.1% | 47.6% |
| Research & Development | 16.58M | 21.94M | 20.84M | 21.61M | 19.4M |
| Selling, General & Admin | 150.67M | 164.67M | 182.35M | 175.65M | 165.07M |
| Operating Expenses | 167.24M | 238.78M | 236.09M | 197.26M | 196.1M |
| Depreciation & Amortization | 21.63M | 23.51M | 18.15M | 21M | 20.66M |
| EBITDA | 30.29M | (9.57M) | (58.34M) | (15.47M) | (2.72M) |
| EBITDA Margin | 8.5% | -2.5% | -18.5% | -4.6% | -0.8% |
| Operating Income | 9.24M | (85.24M) | (109.39M) | (42.52M) | (30.21M) |
| Operating Margin | 2.6% | -22.6% | -34.7% | -12.7% | -8.7% |
| Interest Income | 129K | 2.84M | 6.57M | 5.19M | 2.15M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (581K) | 1.98M | 7.04M | 6.04M | 6.83M |
| Income Before Tax | 8.66M | (83.27M) | (102.34M) | (36.48M) | (23.38M) |
| Pre-Tax Margin | 2.4% | -22.1% | -32.4% | -10.9% | -6.7% |
| Income Tax Expense | 14.99M | 504K | 105K | (588K) | (632K) |
| Net Income | (6.33M) | (83.77M) | (102.45M) | (35.89M) | (22.75M) |
| Net Margin | -1.8% | -22.2% | -32.5% | -10.7% | -6.5% |
| EPS (Basic) | (0.28) | (3.67) | (4.42) | (1.52) | (0.85) |
| EPS (Diluted) | (0.28) | (3.67) | (4.42) | (1.52) | (0.85) |
| Weighted Avg Shares | 22.49M | 22.85M | 23.18M | 23.65M | 27.18M |
| Weighted Avg Shares (Diluted) | 22.49M | 22.85M | 23.18M | 23.65M | 27.18M |
Inogen, Inc.
NASDAQ:INGN
Intrinsic Alpha fair value
Locked
Current Price
$5.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.